Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
blog-list-cover
Recent blog posts
SLURP1 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
SLURP1 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of SLURP1 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
TMC1 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
TMC1 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of TMC1 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
GPNMB Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
GPNMB Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of GPNMB sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
MBTPS2 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
MBTPS2 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of MBTPS2 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
IMMP1L Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
IMMP1L Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of IMMP1L sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
MBTPS1 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
MBTPS1 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of MBTPS1 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
IMMP2L Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
IMMP2L Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of IMMP2L sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
GHITM Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
GHITM Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of GHITM sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
AFG3L2 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
AFG3L2 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of AFG3L2 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
GP2 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
GP2 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of GP2 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
ATP23 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
ATP23 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of ATP23 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
GPC6 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
GPC6 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of GPC6 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →